A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more. Merger with SomaLogic, Inc. On January 5, 2024, we completed our merger with SomaLogic, Inc. ("SomaLogic"), making it our wholly owned subsidiary.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 108M | 174M | 106M | 98M | 131M | 138M |
| Net Income | -128M | -185M | -75M | -190M | -59M | -53M |
| EPS | $-0.33 | $-0.52 | $-0.94 | $-2.43 | $-0.78 | $-0.74 |
| Free Cash Flow | -98M | -152M | -46M | -93M | -57M | -28M |
| ROIC | -45.6% | -39.2% | -23.7% | -29.8% | -62.3% | -38.1% |
| Gross Margin | 49.0% | 48.3% | 47.4% | 37.8% | - | - |
| Debt/Equity | 0.00 | 0.00 | -0.09 | -0.82 | 0.11 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -118M | -175M | -77M | -116M | -67M | -51M |
| Operating Margin | -109.4% | -100.5% | -72.0% | -118.6% | -51.7% | -36.9% |
| ROE | -32.1% | -114.3% | - | -2895.8% | -50.7% | -36.2% |
| Shares Outstanding | 385M | 356M | 379M | 78M | 76M | 72M |
STANDARD BIOTOOLS INC. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 44.5%.
STANDARD BIOTOOLS INC. (LAB) has a 5-year average return on invested capital (ROIC) of -38.6%. This is below average and may indicate limited pricing power.
STANDARD BIOTOOLS INC. (LAB) has a market capitalization of $339M. It is classified as a small-cap stock.
STANDARD BIOTOOLS INC. (LAB) does not currently pay a regular dividend.
STANDARD BIOTOOLS INC. (LAB) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
STANDARD BIOTOOLS INC. (LAB) reported annual revenue of $174 million in its most recent fiscal year, based on SEC EDGAR filings.
STANDARD BIOTOOLS INC. (LAB) has a net profit margin of -106.0%. The company is currently unprofitable.
STANDARD BIOTOOLS INC. (LAB) generated $-152 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
STANDARD BIOTOOLS INC. (LAB) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
STANDARD BIOTOOLS INC. (LAB) reported earnings per share (EPS) of $-0.52 in its most recent fiscal year.
STANDARD BIOTOOLS INC. (LAB) has a return on equity (ROE) of -114.3%. A negative ROE may indicate losses or negative equity.
STANDARD BIOTOOLS INC. (LAB) has a 5-year average gross margin of 44.5%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for STANDARD BIOTOOLS INC. (LAB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
STANDARD BIOTOOLS INC. (LAB) has a book value per share of $1.33, based on its most recent annual SEC filing.